Neogap Therapeutics Presents at Neoantigen Summit Europe in Amsterdam

Neogap Therapeutics, a Swedish clinical-stage biotechnology company developing personalized immunotherapy for cancer, will participate in this year’s Neoantigen Summit Europe in Amsterdam. Ola Nilsson, Head of Neoantigen Production, Development & Clinical Processing, is an invited speaker and will present the company’s cell therapy pTTL and the EpiTCer® technology.

pTTL (personalized Tumor Trained Lymphocytes) is a personalized cell therapy based on the patient’s own T cells, harvested from regional lymph nodes and trained to recognize tumor-specific neoantigens. The treatment is being evaluated in an ongoing Phase I/IIa study for patients with advanced colorectal cancer.

EpiTCer®, Neogap’s proprietary technology, plays a central role in the production of pTTL. By mimicking the body’s natural antigen presentation, it delivers selected neoantigens to the immune system and is also used to develop potency assays – functional tests that measure the potential effect of the treatment.

“Our EpiTCer® technology is very powerful. It not only enables efficient delivery of neoantigens to the immune system and selective expansion of tumor-specific T cells, but also gives us tools to functionally test the potential effect of the treatment. It is a combination that makes Neogap’s method unique in cell therapy,” says Ola Nilsson, Head of Neoantigen Production, Development & Clinical Processing at Neogap Therapeutics.

“Neoantigen Summit is an important international arena to show how we connect technological innovation with clinical application – and at the same time share our perspectives in the global conversation about the future of cancer treatments.”

Neoantigen Summit Europe is a leading international conference in immunotherapy with a special focus on neoantigen-based treatments. The event brings together researchers, clinicians, and industry representatives from around the world.

The conference takes place in Amsterdam on June 24–26, 2025. Ola Nilsson speaks on June 26 at 11:30 AM. For more information, registration, and agenda – visit the event’s website.

Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94
Email: samuel.svensson@neogap.se

About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company developing personalized immunotherapy for the treatment of cancer using the patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is an advanced software that uses DNA sequencing data from the patient and machine learning to select tumor-specific mutations. EpiTCer® is then used to propagate the T cells that can recognize the selected tumor-specific target structures. Neogap is located at Cancer Center Karolinska in Stockholm. For more information about Neogap and its innovative research, visit neogap.se and follow Neogap on LinkedIn.

---

Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.